Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Int. braz. j. urol ; 44(4): 734-739, July-Aug. 2018. tab, graf
Artigo em Inglês | LILACS | ID: biblio-954089

RESUMO

ABSTRACT Purposes: The aim of this study was to determine the diagnostic significance of fibronectin type III domain containing protein 5 (FNDC5)/Irisin levels in the sera of patients with renal cell cancer. Materials and Methods: In the study, 48 individuals were evaluated. The patient group included 23 subjects diagnosed with renal tumor, and the control group of 25 healthy individuals. Patients diagnosed with renal tumor received surgical treatment consisting of radical or partial nephrectomy. Blood specimens were collected and serum FNDC5/Irisin and carcinoembryonic antigen (CEA) levels were determined using enzyme-linked immunosorbent assay (ELISA). Results: FNDC5/irisin and CEA levels in renal cancer patients were significantly higher compared with the control group (p=0.0001, p=0.009, respectively). Also, FNDC5 levels was more sensitive and specific than CEA levels. The best cut-off points for FNDC5/irisin were >105pg/mL and CEA were >2.67ng/mL for renal cancer. Conclusions: FNDC5/Irisin may be used as a diagnostic biomarker for renal cancer.


Assuntos
Humanos , Masculino , Feminino , Adulto , Idoso , Idoso de 80 Anos ou mais , Carcinoma de Células Renais/diagnóstico , Carcinoma de Células Renais/sangue , Antígeno Carcinoembrionário/sangue , Fibronectinas/sangue , Neoplasias Renais/diagnóstico , Neoplasias Renais/sangue , Valores de Referência , Ensaio de Imunoadsorção Enzimática , Carcinoma de Células Renais/patologia , Biomarcadores Tumorais/sangue , Estudos de Casos e Controles , Reprodutibilidade dos Testes , Estudos Retrospectivos , Sensibilidade e Especificidade , Estatísticas não Paramétricas , Gradação de Tumores , Neoplasias Renais/patologia , Pessoa de Meia-Idade , Estadiamento de Neoplasias
2.
Int. braz. j. urol ; 43(5): 966-973, Sept.-Oct. 2017. tab, graf
Artigo em Inglês | LILACS | ID: biblio-892901

RESUMO

ABSTRACT Purpose: Despite the nerve-sparing technique, many patients suffer from erectile dysfunction after radical prostatectomy (RP) due to cavernous nerve injury. The aim of this study was to evaluate dipyridamole as a potential treatment agent of post-radical prostatectomy erectile dysfunction. Material and methods: A total of 18 male Sprague-Dawley rats were randomized into three experimental Groups (SHAM+DMSO, BCNI+DMSO and BCNI+DIP). An animal model of bilateral cavernous nerve crush injury (BCNI) was established to mimic the partial nerve damage during nerve-sparing RP. After creating of BCNI, dimethyl sulphoxide (DMSO) was administered transperitoneally as a vehicle to SHAM+DMSO and BCNI+DMSO Groups. BCNI+DIP Group received dipyiridamole (10mg/kg/day) as a solution in DMSO for 15 days. Afterwards, rats were evaluated for in vivo erectile response to cavernous nerve stimulation. Penile tissues were also analyzed biochemically for transforming growth factor-β1 (TGF-β1) level. Penile corporal apoptosis was determined by TUNEL method. Results: Erectile response was decreased in rats with BCNI and there was no significant improvement with dipyridamole treatment. TGF-β1 levels were increased in rats with BCNI and decreased with dipyridamole treatment. Dipyridamole led to reduced penile apoptosis in rats with BCNI and there was no significant difference when compared to sham operated rats. Conclusions: Although fifteen-day dipyridamole treatment has failed to improve erectile function in rats with BCNI, the decline in both TGF-β1 levels and apoptotic indices with treatment may be helpful in protecting penile morphology after cavernous nerve injury.


Assuntos
Animais , Masculino , Ratos , Prostatectomia/efeitos adversos , Apoptose/efeitos dos fármacos , Dipiridamol/uso terapêutico , Disfunção Erétil/tratamento farmacológico , Pênis/efeitos dos fármacos , Distribuição Aleatória , Ratos Sprague-Dawley , Modelos Animais de Doenças , Disfunção Erétil/etiologia
3.
Int. braz. j. urol ; 43(4): 638-643, July-Aug. 2017. tab
Artigo em Inglês | LILACS | ID: biblio-892869

RESUMO

ABSTRACT Purpose To investigate the efficacy of signal peptide-CUB-EGF domain-containing protein 1 (SCUBE-1) as a novel biomarker of renal tumors. Materials and Methods 48 individuals were included in the study. The patient group (Group-1) consisted of 23 subjects diagnosed with renal tumor, and the control group (Group-2) of 25 healthy individuals. Patients diagnosed with renal tumor received surgical treatment consisting of radical or partial nephrectomy. Blood specimens were collected following overnight fasting. Signal peptide-CUB-EGF domain-containing protein 1 (SCUBE-1), soluble urokinase plasminogen activator receptor (suPAR) and carbonic anhydrase IX (CA IX) levels were measured from plasma samples. Patients in groups 1 and 2 were compared in terms of these biochemical parameters. Results The 23-member renal tumor group was made up of 17 (73.91%) male and 6 (26.08%) female patients with a mean age of 58.5±15.7 years (range 25 to 80). The 24-member healthy control group was made up of 16 (64%) male and 9 (36%) female subjects with a mean age of 52.4±9.12 years (range 40 to 67). Analysis revealed significant elevation in SCUBE-1 levels in the renal tumor group (p=0.005). No significant differences were detected between the groups with regard to CA IX or suPAR measurements (p=0.062 vs. p=0.176). Conclusions SCUBE-1 appears to represent a promising biomarker in the diagnosis and follow-up of patients with renal tumor.


Assuntos
Humanos , Masculino , Feminino , Adulto , Idoso , Idoso de 80 Anos ou mais , Carcinoma de Células Renais/sangue , Receptores de Ativador de Plasminogênio Tipo Uroquinase/sangue , Anidrase Carbônica IX/sangue , Neoplasias Renais/sangue , Proteínas de Membrana/sangue , Proteínas de Ligação ao Cálcio , Carcinoma de Células Renais/diagnóstico , Biomarcadores Tumorais/sangue , Estudos de Casos e Controles , Neoplasias Renais/diagnóstico , Pessoa de Meia-Idade
4.
Int. braz. j. urol ; 42(1): 146-153, Jan.-Feb. 2016. tab, graf
Artigo em Inglês | LILACS | ID: lil-777330

RESUMO

ABSTRACT Purpose To investigate the protective effects against ischemia reperfusion injury of dipyridamole in a model of induced priapism in rats. Materials and Methods Twenty-four male Sprague-Dawley rats were divided into four groups, control, P/R, P/R+DMSO and P/R+D. 3ml blood specimens were collected from vena cava inferior in order to determine serum MDA, IMA, TAS, TOS and OSI values, and penile tissue was taken for histopathological examination in control group. Priapism was induced in P/R group. After 1h, priapism was concluded and 30 min reperfusion was performed. In P/R+DMSO group 1ml/kg DMSO was administered intraperitoneally 30 min before reperfusion, while in P/R+D group 10mg/kg dipyridamole was administered intraperitoneally 30 min before reperfusion. Blood and penis specimens were collected after the end of 30 min reperfusion period. Sinusoidal area (µm2), tears in tunica albuginea and injury parameters in sinusoidal endothelium of penis were investigated. Results Histopathological examination revealed no significant changes in term of sinusoidal area. A decrease in tears was observed in P/R+D group compared to P/R group (p<0.05). Endothelial injury decreased in P/R+D group compared to P/R group (p>0.05). There were no significant differences in MDA and IMA values between groups. A significant increase in TOS and OSI values was observed in P/R+D group compared to P/R group. A significant decrease in TAS levels was observed in P/R+D group compared to the P/R group. Conclusions The administration of dipyridamole before reperfusion in ischemic priapism model has a potential protective effect against histopathological injury of the penis.


Assuntos
Animais , Masculino , Pênis/irrigação sanguínea , Priapismo/prevenção & controle , Vasodilatadores/farmacologia , Traumatismo por Reperfusão/prevenção & controle , Dipiridamol/farmacologia , Isquemia/prevenção & controle , Pênis/patologia , Priapismo/patologia , Fatores de Tempo , Ereção Peniana/efeitos dos fármacos , Albumina Sérica , Biomarcadores/sangue , Distribuição Aleatória , Reprodutibilidade dos Testes , Resultado do Tratamento , Oxidantes/sangue , Ratos Sprague-Dawley , Estresse Oxidativo , Precondicionamento Isquêmico/métodos , Modelos Animais de Doenças , Albumina Sérica Humana , Malondialdeído/sangue , Antioxidantes/análise
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA